{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:41:46Z","timestamp":1790109706263,"version":"4.0.1"},"reference-count":75,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Clinical Pharmacology"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1586\/ecp.09.3","type":"journal-article","created":{"date-parts":[[2009,5,6]],"date-time":"2009-05-06T10:48:20Z","timestamp":1241606900000},"page":"239-253","source":"Crossref","is-referenced-by-count":13,"title":["Solifenacin: pharmacology and clinical efficacy"],"prefix":"10.1586","volume":"2","author":[{"given":"Dudley","family":"Robinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Cardozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10052"},{"key":"CIT0002","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1471-0528.1997.tb11006.x","volume":"104","author":"Kelleher","year":"1997","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"CIT0003","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1471-0528.1997.tb12054.x","volume":"104","author":"Kelleher","year":"1997","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"CIT0004","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/bmj.326.7394.841","volume":"326","author":"Herbison","year":"2003","journal-title":"BMJ"},{"key":"CIT0005","first-page":"CD003781","volume":"4","author":"Nabi","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"CIT0006","first-page":"S66","volume":"12","author":"Stewart","year":"2001","journal-title":"Int. Urogynaecol. J."},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.09.019"},{"key":"CIT0009","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0090-4295(97)00595-5","volume":"50","author":"Andersson","year":"1997","journal-title":"Urology"},{"key":"CIT0010","first-page":"484","volume":"23","author":"Hashim","year":"2004","journal-title":"Neurourol. Urodyn."},{"key":"CIT0011","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0031-6997(24)01362-0","volume":"50","author":"Caulfield","year":"1998","journal-title":"Pharmacol. Rev."},{"key":"CIT0012","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0022-5347(01)65752-5","volume":"156","author":"Yamaguchi","year":"1996","journal-title":"J. Urol."},{"key":"CIT0013","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0022-5347(01)67039-3","volume":"154","author":"Harris","year":"1995","journal-title":"J. Urol."},{"key":"CIT0014","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/sj.bjp.0706780","volume":"148","author":"Abrams","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"CIT0015","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0024-3205(98)00581-5","volume":"64","author":"Hegde","year":"1999","journal-title":"Life Sci."},{"key":"CIT0016","first-page":"1654","volume":"275","author":"Braverman","year":"1998","journal-title":"Am. J. Physiol."},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2003.07.019"},{"key":"CIT0018","unstructured":"Ikeda K. Affinity of YM905 for human muscarinic M1, M2 and M3 receptors. Yamanouchi Pharmaceutical Co. Ltd. Registration No: D199803214-02.00. International Study ID: 905-PH-002 (1998)."},{"key":"CIT0019","unstructured":"Suzuki M. Inhibitory effect of YM905 on carbachol-induced contraction of guinea pig urinary bladder. Yamanouchi Pharmaceutical Co. Ltd. Registration No: D9803231-1. International Study ID: 905-PH-007 (1998)."},{"key":"CIT0020","unstructured":"Ikeda K, Kobayashi S. Effects of YM905, oxybutynin and darifenacin on carbachol induced intracellular calcium mobilization by dispersed longitudinal smooth muscle cells of guinea pig colon. Yamanouchi Pharmaceutical Co. Ltd. Registration No. D199803320-02.00. International Study ID: 905-PH-006 (1998)."},{"key":"CIT0021","unstructured":"Ikeda K, Kobayashi S. Effects of YM905, tolterodine and oxybutynin on M3 receptor mediated cytosolic free Ca2+mobilization in acutely dissociated cells of guinea pig urinary bladder smooth muscle and murine submandibular gland. Yamanouchi Pharmaceutical Co. Ltd. Registration No: D199803217-02.000. International Study ID: 905-PH-005 (1998)."},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.30.2324"},{"key":"CIT0023","unstructured":"Saitoh C, Iizumi Y. Effect of YM-67905 on mictuition reflex in anesthetised rats. Yamanouchi Pharmaceutical Co. Ltd. Registration No: D9802853-1. International Study ID: 905-PH-011 (1998)."},{"key":"CIT0024","unstructured":"Ikeda K. Effect of chronic doses of YM905 on carbachol induced salivary secretion in mice. Yamanouchi Pharmaceutical Co. Ltd. Registration No: D199803318-02.00. International Study ID: 905-PH-020 (1998)."},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2004.03.044"},{"key":"CIT0026","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1532-5415.1998.tb01006.x","volume":"46","author":"Katz","year":"1998","journal-title":"J. Am. Geriatr. Soc."},{"key":"CIT0027","unstructured":"Yanagihara T. Plasma concentrations of the unchanged drug after repeated oral administration of YM905 to dogs. Yamanouchi Pharmaceutical Co. Ltd Registration No: D9803132-1. International Study ID: 905-ME-004 (1998)."},{"key":"CIT0028","unstructured":"Yanagihara T. Plasma concentrations of the unchanged drug and its metabolite BY-348C after single intravenous and oral administration of YM905 to rats. Yamanouchi Pharmaceutical Co. Ltd. Registration No: D9802939-1. International Study ID: 905-ME-002 (1998)."},{"key":"CIT0029","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2125.2004.02097.x","volume":"58","author":"Ucida","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"CIT0030","unstructured":"Yanagihara T. Plasma concentrations of the unchanged drug after single intravenous and oral administration of YM905 in dogs. Yamanouchi Pharmaceutical Co. Ltd. Registration No: D9802940-1. International Study ID: 905-ME-003 (1998)."},{"key":"CIT0031","unstructured":"Yanagihara T.In vitroplasma protein binding of YM905. Yamanouchi Pharmaceutical Co Ltd. Registration No.: D199803314-02.00. International study ID: 905-ME-007 (1998)."},{"key":"CIT0032","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2165\/00126839-200405020-00002","volume":"5","author":"Kuipers","year":"2004","journal-title":"Drugs RD"},{"key":"CIT0033","unstructured":"Yanagihara T. Comparison ofin vitrometabolic patterns of YM905 among various species. Yamanouchi Pharmaceutical Co Ltd. Registration No: D9803351-1. International study ID: 905-ME-009 (1998)."},{"key":"CIT0034","unstructured":"Onderwater RCA. Identification of human liver CYP isoforms involved in the metabolism of YM905. Yamanouchi Europe BV. Registration No: D199900072-01.00. International Study ID: 905-ME-020 (1999)."},{"key":"CIT0035","unstructured":"Nakamura E. Absorption, distribution, metabolism and excretion of radioactivity after oral administration of 14C-YM905 to rats. Yamanouchi Pharmaceutical Co Ltd. Registration No: D9802237-1 International Study ID: 905-ME-001 (1997)."},{"key":"CIT0036","first-page":"138","volume":"21","author":"Smith","year":"2002","journal-title":"Neurourol. Urodyn."},{"key":"CIT0037","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1464-410X.2004.04561.x","volume":"93","author":"Chapple","year":"2004","journal-title":"BJU Int."},{"key":"CIT0038","unstructured":"Chapple CR, Arano P, Bosch JLHR, De Ridder D, Kramer AEJL, Ridder AM. YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo and tolterodine controlled Phase II dose finding study. Poster 75.32nd Annual Meeting of the International Continence Society. Heidelberg, Germany, 28\u201330 August 2002."},{"key":"CIT0039","first-page":"381","volume":"21","author":"Chapple","year":"2002","journal-title":"Neurourol. Urodyn."},{"key":"CIT0040","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0020-7292(03)00185-1","volume":"83","author":"Gittelman","year":"2003","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000140729.07840.16"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2003.04681.x"},{"key":"CIT0043","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.eururo.2004.11.004","volume":"7","author":"Haab","year":"2005","journal-title":"Eur. Urol."},{"key":"CIT0044","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.eururo.2005.06.007","volume":"48","author":"Abrams","year":"2005","journal-title":"Eur. Urol."},{"key":"CIT0045","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s00192-005-0058-6","volume":"17","author":"Cardozo","year":"2006","journal-title":"Int. Urogynaecol. J."},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X74907"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjopharm.2006.03.004"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.05.015"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.05.027"},{"key":"CIT0050","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.clinthera.2008.10.011","volume":"30","author":"Chancellor","year":"2008","journal-title":"Clin. Ther."},{"key":"CIT0051","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1464-410X.2007.07031.x","volume":"100","author":"Yamaguchi","year":"2007","journal-title":"BJU Int."},{"key":"CIT0052","unstructured":"Wesnes K, Edgar C, Tretter R, Patel H, Bolodeoku J. Solifenacin is not associated with cognitive impairment or sedation in the elderly; the randomised double-blind SCOPE study. Poster presentation.38th Annual Meeting of the International Continence Society, Cairo, Egypt, 2008."},{"key":"CIT0053","unstructured":"Mattiasson A, Morton R, Bolodeoku J. Solifenacin alone and with simplified bladder retraining in overactive bladder syndrome: the prospective randomised SOLAR study. Poster Presentation.38th Annual Meeting of the International Continence Society, Cairo, Egypt, 20\u201324 October 2008."},{"key":"CIT0054","doi-asserted-by":"crossref","unstructured":"Garley AD, Kaufman JM, Sand PK, Smith N, Andoh M. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the Vesicare Open Label Trial.Clin. Ther.28, 1935\u20131946 (2006).","DOI":"10.1016\/j.clinthera.2006.11.010"},{"key":"CIT0055","unstructured":"Lucente V, Ostergard D, Davila GW, Forero-Schwanhaeuser S. Patient reported outcomes in 3 cohorts of patients defined by length of time as acute or chronic overactive bladder: an analysis of more than 2200 patients in the Vesicare open label trial (VOLT).37th Annual Meeting of the International Continence Society. Rotterdam, The Netherlands, August (2007)."},{"key":"CIT0056","unstructured":"Capo JP, Lucente V, Forero-Schwanhaeuser S. Solifenacin use in elderly patients with overactive bladder: VOLT and VERSUS data. Poster Presentation.38th Annual Meeting of the International Continence Society, Cairo, Egypt, October (2008)."},{"key":"CIT0057","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1464-410X.2005.05294.x","volume":"95","author":"Chapple","year":"2005","journal-title":"BJU Int."},{"key":"CIT0058","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/j.1464-410X.2008.07939.x","volume":"102","author":"Cardozo","year":"2008","journal-title":"BJU Int."},{"key":"CIT0059","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.urology.2008.08.485","volume":"73","author":"Karram","year":"2009","journal-title":"Urology"},{"key":"CIT0060","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000155798.78911.57"},{"key":"CIT0061","doi-asserted-by":"crossref","first-page":"227","DOI":"10.5414\/CPP43227","volume":"43","author":"Krauwinkel","year":"2005","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"CIT0062","unstructured":"Fuder H. A double blind, randomised, placebo controlled rising study in elderly male and female volunteers to evaluate safety, tolerability and pharmacokinetics of multiple dosing with YM905. Yamanouchi Europe BV. Registration No: D9803294\u20131. International Study ID: 905-CL-004."},{"key":"CIT0063","unstructured":"Van Aplen WW. A placebo controlled dose rising study in healthy male volunteers to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of single oral dosages of YM905. Clinical Pharmacology Research Department, Yamanouchi Europe BV. Registration No: D200001570-01.00. International Study ID: 905-CL-001(1998)."},{"key":"CIT0064","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1742-7843.2006.pto_285.x","volume":"99","author":"Swart","year":"2006","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"CIT0065","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.09.002"},{"key":"CIT0066","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2125.2006.02638.x","volume":"62","author":"Smulders","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.FP0060754"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.FP0060311"},{"key":"CIT0069","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831060-00005"},{"key":"CIT0070","unstructured":"Hoebeke P, Decaestecker K, Raes A, Dehoorne J, Vande Walle J, Van Laecke E. Safety and efficacy of solifenacin in the treatment of therapy resistant overactive bladder of childhood.XVII Annual Congress of the European Society Paediatric Urology. Athens, Greece, 27\u201329 April 2006."},{"key":"CIT0071","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1464-410X.2007.06905.x","volume":"100","author":"Kroll","year":"2007","journal-title":"BJU Int."},{"key":"CIT0072","author":"Hakkaart","year":"2008","journal-title":"Int. Urol. Nephrol."},{"key":"CIT0073","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1185\/03007990802234829","volume":"24","author":"Speakman","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"CIT0074","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur. Urol."},{"key":"CIT0075","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.06.080"}],"container-title":["Expert Review of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/ecp.09.3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T08:50:09Z","timestamp":1739091009000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1586\/ecp.09.3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":75,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,1,10]]},"published-print":{"date-parts":[[2009,5]]}},"alternative-id":["10.1586\/ecp.09.3"],"URL":"https:\/\/doi.org\/10.1586\/ecp.09.3","relation":{},"ISSN":["1751-2433","1751-2441"],"issn-type":[{"value":"1751-2433","type":"print"},{"value":"1751-2441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}